1. Krishnamurti U, Silverman JF (2014) HER2 in breast cancer: a review and update. Adv Anat Pathol 21(2):100–107. doi: 10.1097/PAP.0000000000000015
2. Perez EA, Cortes J, Gonzalez-Angulo AM, Bartlett JM (2014) HER2 testing: current status and future directions. Cancer Treat Rev 40(2):276–284. doi: 10.1016/j.ctrv.2013.09.001
3. Garrison LP Jr, Veenstra DL (2009) The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer. Value Health 12(8):1118–1123. doi: 10.1111/j.1524-4733.2009.00572.x
4. Rakha EA, Pinder SE, Bartlett JM, Ibrahim M, Starczynski J, Carder PJ, Provenzano E, Hanby A, Hales S, Lee AH, Ellis IO, National Coordinating Committee for Breast P (2015) Updated UK Recommendations for HER2 assessment in breast cancer. J Clin Pathol 68(2):93–99. doi: 10.1136/jclinpath-2014-202571
5. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF, American Society of Clinical Oncology/College of American P (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131(1):18–43. doi: 10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2